Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DTRMWXHS-12 |
Synonyms | |
Therapy Description |
DTRMWXHS-12 inhibits BTK, resulting in decreased B-cell receptor (BCR) signaling and potentially leading to reduced tumor cell growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DTRMWXHS-12 | DTRM-12|DTRMWXHS 12 | BTK inhibitor 37 | DTRMWXHS-12 inhibits BTK, resulting in decreased B-cell receptor (BCR) signaling and potentially leading to reduced tumor cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02900716 | Phase I | DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | Completed | USA | 0 |